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Abstract
DM is considered as the cause of accelerated aging. Numerous biomedical studies have 
proved the key role of neuroimmune-endocrine interactions in the human body, which 
trigger the universal molecular pathways in the development of aging and DM (GH/IGF-1,  
Ras-MAPK, FOXO3A, sirtuin, mTOR, CETP, Timeless gene, TZAP pathways). Modern 
methods of proteomic and bioinformatic analysis allow us to investigate key genomic-
proteomic interactions that underlie diabetic nephropathy (DN) in patients with type 2 
DM. The study of the formation and development of DN can become the model for study-
ing molecular pathways of aging of kidney tissue. Future biomedical research based on 
methods of high-throughput screening (HTS) of a pool of target molecules will lead to great 
advances in the diagnosis of aging stages and DM, as well as the development of methods 
for the prevention and therapy of accelerated aging of the human body and various vio-
lations of carbohydrate metabolism (1D-2D/MALDI-TOF-MS, HTS, biochips, biosensors).
Keywords: aging, diabetes mellitus, pathway, gene expression, proteomics
1. Introduction
The latest data show that the prevalence of diabetes mellitus (DM) in the world has increased 
more than in two times, peaking at 415 million by the end of 2015 [1]. In accordance with the 
current evaluation of the International Diabetes Federation, 642 million patients will be with 
DM by 2040 [2]. Increased incidence of DM caused the adoption of the United Nations (UN) 
resolution 61/225 dated 20 December 2006 about DM. In the 2011, political declaration was 
adopted by the UN to the national healthcare systems to create a multidisciplinary strategy 
in the area of prevention and control of noninfectious diseases, where particular attention is 
drawn to the problem of DM as one of the leading causes of disability and mortality [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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There is significant increase of the prevalence of DM in the Russian Federation. According 
to the Federal Register of Diabetes Mellitus, at the end of 2016, 4.35 million outpatients 
with  DM (3% of the total population) were registered in Russia, of whom 92% (4 million 
people) had type 2 DM, 6% (255,000 people) - type 1 DM and 2% (75,000 people) -other 
types of DM. Actual number of patients with DM remains underestimated, since only iden-
tified and reported cases are considered. The results of the large-scale Russian epidemio-
logical study NATION confirmed that only 50% of type 2 DM cases are diagnosed. Actual 
number of patients with DM can be at least 8-9 million people (about 6% of the population) 
in Russia [4]. Because of the lack of timely diagnostics of DM, some patients do not receive 
necessary therapy and have higher risk of the developing of such complications of DM as 
retinopathy, nephropathy, ischemic heart disease, cerebral ischemia, peripheral angiopa-
thy. These complications are responsible for most cases of disability and mortality of DM.
Today, DM is considered as the cause of accelerated aging [5]. Twenty percent of middle-
aged people and 35% of the population of older persons are characterized by varying degrees 
of impaired glucose tolerance (IGT) and symptoms of insulin resistance. An increase in the 
frequency of obesity and sedentary lifestyle and the major risk factors for type 2 DM sug-
gests that the prevalence of DM in the world will increase. The management of this disease 
becomes difficult for persons aged 60, 70 and 80 years. The risk of complications, such as isch-
emic heart disease, increases with age, as well as damage with age of organs of vision, hearing 
and physical activity, can amplify in the presence of DM.
The modern stage of the development of researches in the field of DM and aging is inter-
related and involves the use of unified technological platforms for molecular diagnostics 
and pharmacology of stages of aging and DM. Unified technological platforms presuppose 
the performing of comparative genomic and proteomic studies, the results of which allow 
to study interrelated pathogenesis of aging and DM. Also new technological platforms are 
necessary for the development of new prophylaxis and treatment of these interconnected 
pathological states. The analysis of data from comparative genomic and proteomic studies 
allows the formation of unified molecular pathological pathways of DM and aging. The chap-
ter presents new technological platforms for the early identification and the development of 
anti-aging and anti-diabetic agents.
2. Neuroimmune and neuroendocrine communications: aging, metabolic 
syndrome and diabetes mellitus
Aging is a universal factor for metabolic and immune disorders in humans and related dis-
eases, including DM [6]. So, analysis of the reciprocal effect of neuroendocrine factors and 
immunological processes at the system level, human organs and tissues is very important. It 
is the basis for the development of processes of aging and the emergence of DM formation of 
mechanisms at cellular and molecular levels.
The maintenance of the homeostasis of nervous and immune systems is carried out by com-
parable number of cellular elements. The integration of nervous and immune systems is due 
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to the presence of neuronal processes, receptors and neurotransmitters in the nervous system, 
as well as the presence of highly mobile cell elements and cytokines in the immune system 
[7]. The search of opportunities of the  influence to immune processes through the central ner-
vous system in the order to prevent of aging and metabolic disorders is based on fundamental 
laws of hierarchical organization of regulatory system, the presence of humoral signals in cell 
populations, the points of application of the effect in tissues and organs. The information in 
the nervous system is encoded in the sequence of electrical impulses and in the architecture of 
neuronal interactions, in the immune system information is stored in stereochemical configu-
ration of molecules and receptors involved in lymphocyte interactions. There was evidence of 
a common receptor apparatus in the immune system to neuromediators and nervous system to 
endogenous immunomodulators. Immunological active neuroendocrine substances - thymo-
sin, triiodothyronine (T3) and thyroxine (T4), protimosin, endogenous regulator of protimosin, 
parathymosin, oxytocin, Th-I antigen and vasoactive intestinal peptide have been found both 
in the brain and in the thymus, they play significant role in the aging of human immune sys-
tem [8]. The greatest number of studies are devoted to the participation of interleukin 1 (IL-1), 
in immunoregulation at the level of immunocompetent cells and in regulation of functions. 
Interleukin 2 (IL-2) also exerts various effects on the immune and nervous systems mediated 
by affinity binding to the corresponding cell surface receptors. The activating effect of IL-2 on 
lymphocytes and macrophages is manifested in the enhancement of the antibody-dependent 
cytotoxicity of these cells with parallel stimulation of the secretion of tumor necrosis factor α 
(TNF-α). IL-2 induces proliferation and differentiation of oligodendrocytes, affects the reac-
tivity of the hypothalamus neurons and increases the level of adrenocorticotropic hormone 
(ACTH) and cortisol in the blood, which together form a stable mechanism of neuroimmune 
and neuroendocrine network interactions. Cells that are targets for the action of IL-2 are 
T-lymphocytes, natural killers (NK), and macrophages. IL-2 causes the functional activation 
of these cell types and the secretion of other cytokines, for example, increases the production 
of NK cells by interferon γ (IFN-γ) [9]. There are data about the production of nervous cells of 
IL-1, IL-6 and TNF-α, which are critical components in the development of chronic inflamma-
tion with destruction of β-cells of the pancreas in DM type 2 [10]. It is known that glucocorti-
coids (GCs), androgens, estrogens and progesterone suppress immune responses, and growth 
hormone (GH), T4 and insulin have a stimulating effect [11, 12]. Cells of the immune system 
transmit transmembrane signal to receptors for GCs, insulin, GH, estradiol, testosterone, beta-
adrenergic agents, acetylcholine, endorphins and enkephalins [13]. All of above-mentioned 
hormonal factors are involved in the formation of metabolic and immunological changes in 
conditions of aging and DM. For example, the exogenous administration of contra-insular 
hormones T3 and T4 alters functional activity of the immune system. This action is realized 
through cytoplasmic and nuclear receptors in immune cells [14, 15]. The theory of aging sug-
gests that life expectancy has negative relationship with metabolic rate, which is regulated by 
hormones of energy metabolism. Experimental hypothyroidism increased life expectancy in 
young rats, whereas hyperthyroidism shortened life expectancy. Several mutant mice in long 
life experiment had reduced or almost absent thyroid function [16–18]. Hypothyroidism can 
affect life expectancy by reducing the intensity of metabolism, body temperature and oxygen 
consumption, resulting in a decrease in the generation of free oxygen radicals and associ-
ated oxidative damage in cells. Subclinical hypothyroidism is associated with a reduction 
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in mortality in women, which was found in families with long life expectancy and is due to 
polymorphism of the receptor to thyroid stimulating hormone (TSH) [19]. An important fact 
is that subclinical hypothyroidism is often recorded with type 2 DM [20].
Most of the data indicate the role of insulin as one of the growth factors that support the 
readiness of lymphoid cells to realize the response to an antigen. The stimulating effect of 
this hormone is manifested mainly in conditions of the pathology of the immune system with 
DM. Proliferative activity of lymphoid cells is reduced in patients with insufficient insulin 
production; first of all, functions of T cells suffer [21]. Antagonistic pleiotropic hypothesis 
of aging suggests that some pathological pathways that are evolutionarily necessary for the 
development of the human body and reproductive function become unfavorable with aging 
of the human body. For example, the increase of the ratio of GH / insulin-like growth factor-1 
(IGF-1) is necessary for the growth and maturation during puberty. GH secretion decreases 
with age, resulting in a corresponding decrease in IGF-1 concentration. Low levels of IGF-1 in 
the human body are associated with an increased risk of developing type 2 DM [22].
GCs are the most studied and effective participants in pathological changes in neuroimmu-
noendocrine network interactions that occur in patients with DM. Genes that are targets of 
GCs are responsible for the synthesis of protein molecules involved in virtually all parts of 
immunological process in DM [23]. GCs inhibit the synthesis of IL-1, TNF-α, granulocyte-
macrophage colony-stimulating factor (GM-CSF), IL-3, 4, 5, 6, 8 and reduce the induction 
of NO synthase, which leads to the decrease of NO synthesis and pro-inflammatory effect 
through cyclooxygenase, phospholipase A2, endothelin-1, involved in cardiovascular remod-
eling in aging and DM [24, 25]. On the other hand, GCs enhance the synthesis of proteins 
that have an anti-inflammatory effect, including the synthesis of lipocortin-1, which inhibits 
the activity of phospholipase A2 and the production of leukotrienes (C4, D4, E4), as well as 
prostaglandin E2 and leukotriene B4 [26]. GCs are inducer of type II receptors for IL-1, which 
has an anti-inflammatory effect. GCs inhibit the enhanced TNF-α transcription of the IL-8 
gene [27]. Feedback in neuroendocrine interaction is carried out by cells that originate from 
lymphocytes through the hypothalamic-pituitary-adrenal system.
So, the nervous, immune and endocrine systems fulfill their specific functions with the help 
of identical mechanisms and are interrelated.
Insulin resistance is the main component of the metabolic syndrome and is very often found in 
elderly patients. Abdominal obesity, which is often found with human aging, is the main cause 
of insulin resistance and metabolic syndrome [28]. Aging is also associated with an increase in 
the level of proinflammatory cytokines that interact with insulin. Cytokines are isolated from 
adipose tissue, and cytokine synthesis increases with age, it is associated with aging. It has 
been shown that the synthesis of cytokines increases by aging cells [29]. Glucostatic theory was 
formulated by J. Mayer, who described a feedback system that maintains the level of glycemia. 
In accordance with this theory, the hypothalamus controls the absorption of nutrients through 
receptors that respond to changes in glycemia [30].
The interaction of metabolic disorders and the distribution of adipose tissue in the human 
body constitute links in the vicious circle that can accelerate the aging process and the onset 
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of DM development. Lipostatic theory postulates the existence of a feedback mechanism 
between the amount of fat stored by the body, nutritional behavior and fat burning.
The theory predicts the presence of chemical signal produced in adipose tissue, which 
controls food behavior, physical and metabolic activity [31]. In 1994, leptin was discovered, 
that is, produced by adipocytes, moves with blood to the brain and acts on the hypotha-
lamic receptors, suppressing the appetite [32]. Decreased leptin concentration leads to the 
development of obesity and is considered as one of the factors of the pathogenesis of type 
2 DM. There is an increased level of cortisol, heat release, the restriction of growth, the lack 
of reproductive function, unlimited appetite and insulin resistance in mice with the ob/
ob genotype. Leptin receptors belong to the family of cytokine receptors of class 1 and are 
present in the hypothalamus, fatty tissue, liver, skeletal muscles, pancreas, ovaries, pros-
tate, placenta, kidneys and lungs. Leptin reaches the arcuate nuclei of the hypothalamus, 
interacts with its receptors in centers of hunger and satiety and reduces appetite. The bind-
ing of leptin activates the release of adrenaline, which increases the level of cAMP and the 
activity of protein kinase A through the adrenergic α-3 receptors, and triggers the synthesis 
of thermogenin, which converts mitochondria of adipocytes into unconjugated state [33].
In the arcuate nuclei of the hypothalamus, energy consumption is controlled by two types of 
neurons: orexigenic neurons stimulate the appetite by producing and releasing neuropeptide 
Y (NPY), which acts on the next neuron sending the brain a signal to eat. The concentration of 
NPY in the blood rises during fasting. It is the high level of peptide NPY that causes obesity in 
mice od/od and db/db [34]. Anorexigenic neurons of arcuate nuclei of the hypothalamus pro-
duce α-melanocyte-stimulating hormone (α-MSH). The release of α-MSH results in the next 
neuron sending a signal to the brain to stop eating. Mutations in the melanocortin receptor, 
which is expressed in the brain cells and plays a role in the regulation of appetite, lead to the 
appearance of obesity and type 2 DM [35]. Insulin acts on the hypothalamic receptors, sup-
pressing appetite by inhibiting the release of NPY by the orexigenic neurons and also stimu-
lating the production of MCH by anorexigenic receptors, reducing food intake and increasing 
thermogenesis. Leptin makes the liver and muscle cells more sensitive to insulin.
Adiponectin—a protein, consisting of 224 amino acids, is encoded by the ADIPOQ gene and 
secreted by adipocytes under the action of insulin. Adiponectin regulates energy homeostasis, 
has anti-inflammatory and anti-atherogenic effects. Its level decreases with obesity and is asso-
ciated with glucose metabolism. Adiponectin increases the absorption of fatty acids by myo-
cytes and the rate of β-oxidation of fatty acids in muscles, blocks the synthesis of fatty acids 
and gluconeogenesis in hepatocytes and stimulates the absorption and metabolism of glucose 
in muscles and the liver. These effects of adiponectin are provided by increasing the level of 
cAMP and activating cAMP-dependent protein kinase. A low level of adiponectin is character-
istic for obesity, DM and cardiovascular diseases [36]. The similarity of adiponectin to TNF-α 
was found.
TNF-α is one of the key pro-inflammatory cytokines, secreted by macrophages and released 
by adipose tissue cells. One of the main targets of TNF-α is the adipocytes themselves, where 
it blocks the transcription of several genes and activates the expression of others. These effects 
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can lead to insulin resistance, chronic inflammation with systemic consequences for the body. 
Many genes transcribed by TNF-α are activated by the transcription factor in NF-κB adipose 
tissue cells.
The peroxisome proliferator-activated receptors (PPARs) alter gene expression, affecting the 
metabolism of fats and carbohydrates in response to changes in lipid levels in food. Ligands 
of these transcription factors are fatty acids and their derivatives. PRAPs act on the nucleus 
of the cell by forming heterodimers with another nuclear receptor—retinoid X receptor (RXR) 
that binds to regulatory regions of DNA. PPARs include genes necessary for β-oxidation of 
fatty acids and the formation of ketone bodies during fasting and stimulate the expression 
of genes encoding proteins that provide β-oxidation and dissipation of energy due to the 
formation of mismatched mitochondria. In mice with non-functioning receptor, leptin-acti-
vated PPAR-γ prevents the development of obesity by stimulating the synthesis of proteins 
involved in the cleavage of fatty acids and thermogenesis [37].
Ghrelin is a peptide hormone consisting of 28 amino acids produced by P/D1 cells of mucous 
membrane of the fundus of the stomach. Ghrelin receptors are expressed by neurons in the 
arcuate nucleus and ventromedial hypothalamus, here the processes associated with the 
action of ghrelin are mediated: stimulation of the production of releasing hormones, increased 
appetite, changes in the level of glucose and lipid metabolism, regulation of secretion and 
contractions of walls of the gastrointestinal tract [38]. It stimulates the release of GH. The 
concentration of ghrelin in the blood increases before eating and falls immediately after its 
intake. The concentration of ghrelin in the blood plasma increases with age, which contributes 
to weight gain in people as they age [39].
Consequently, numerous biomedical studies have proved the key role of neuroimmune-
endocrine interactions in the human body, which trigger the universal molecular pathological 
pathways in the development of aging and DM.
3. The complex role of molecular pathways in the aging process and DM
Human body cells constantly receive signals from the body and the environment, causing 
processes such as damage, infection and stress. The modern field of research, called “epi-
genetics,” explores how the environment and time affect the functioning of genes and the 
development, health and aging of humans. Some epigenetic changes are serious triggers for 
the development of DM or conditions that increase the risk of developing related DM to age. 
The response to internal and external signals from cells and the production of these signals 
occurs through biological pathways that are important for the development of aging and 
DM, including oxidative stress and/or cellular metabolism. Everyday millions of destructive 
events occur in the DNA structure, but in cells there are powerful mechanisms that protect 
DNA from damage, and these mechanisms remain active in old age.
Today, the goal is to sequester 100 genes in 1000 healthy elderly people, which can shed 
light on the inherited variability that underlies the protection of some people from aging 
diseases, including DM, enabling them to live a healthy life at their age. Sequencing allows 
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researchers to determine whether the presence of mutation carrier makes the elderly more 
secure or more vulnerable to the effects of damaging factors. Topol et al. perform study com-
pared genetic sequencing in healthy volunteers, aged 80 years, and persons whose death 
has been linked to diseases associated with aging, including type 2 DM [40]. Scientists are 
finding that healthy people have an extremely low probability of genetic variations associ-
ated with the development of the disease. This fact proves the idea that protective genes 
play major role in the successful aging people. Therefore, the identification of molecular 
bases of protective effect would develop similar medicines, including effective means of 
preventing type 2 DM. Barzilai et al. sequenced several candidate genes of centenarians, 
including a variant gene that modifies the mechanism of cholesterol metabolism [41]. 
Scientists have sequenced genes of IGF1, its receptor and have identified mutations that are 
unique to women aged 100 years [42]. Calorie restriction increases life span and reduces 
age-related deterioration of work systems and physiological responses of age-related dis-
eases, including with the development of DM. Restriction of caloric intake in animals in the 
experiment leads to a decrease in the level of glucose and insulin in the blood plasma and 
reduces inflammatory responses and the intensity of oxidative stress.
Genetic analysis identified several genes that affect life span and associated with dam-
age to the pituitary development, the decrease of the secretion of GH, food intake and 
apoptosis. The work of these genes converges in the region of the IGF-1 receptor pathway 
and reproduces many effects of limiting calorie intake. Although dwarf mice having the 
defect in the synthesis of GH or the IGF-1 signaling pathway are also characterized by an 
increase of life expectancy, people with signaling defects associated with GH are prone 
to the development of diseases associated with aging. One of the targets of IGF-1, the sig-
nal pathway within the cell, is the repression of proteins responsible for stress resistance, 
including SOD and heat shock proteins, as well as a decrease in IGF signaling can increase 
life expectancy by increasing the expression of genes responsible for stress resistance. The 
mutation of the receptor to IGF-1, a phosphorylation target (p66 Shc), also increases the 
life span without affecting other organs and systems. When Shc is activated, the levels of 
intracellular oxygen radicals increase, suppressing the factor FKHRL1, which is involved 
in apoptosis (Figure 1).
Let us consider the scheme of molecular pathological pathway insulin/IGF-1 in humans, 
where mechanisms of aging and the appearance of type 2 DM are converging.
IGF-1 and IGF-1R provide the activity of proliferative signaling system that stimulates growth 
in many cell types and blocks apoptosis. In vivo, IGF-1 acts as an immediate response to 
effects of many growth factors and GH. One of the components of IGF-1, mitogenic signaling, 
is associated with the tyrosine kinase receptor via Shc, Grb2 and Sos-1, activating the RAS 
and MAP kinase cascade (raf, Mek, Erk). The end point of the MAP kinase pathway is the 
modification of the activity of transcription factors, such as the activation of ELK transcrip-
tion factors. The serum response factor (SRF) and AP-1 provide mitogenic activity of many 
growth factors. IGF-1R signals for cellular survival and growth in response to IGF-1 and IGF-
2. IGF-1R activates three signaling pathways that converge on the phosphorylation process 
of the BAD protein and block apoptosis. The first pathological pathway is activated by the 
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IGF-1R PI3 kinase, and the AKT signaling pathway phosphorylates BAD and blocks apopto-
sis. The second pathological pathway is activated by IGF-1R involving the Ras-Map-kinase 
pathway with the blockade of apoptosis. The third pathological pathway involves the interac-
tion of Raf with mitochondria in the response to the activation of IGF-1R. The similarity of 
these pathological ways blocks apoptosis and increases the response to IGF-1R stimulation. 
The function of proapoptotic BAD molecule is regulated by the phosphorylation of three sites 
(ser 112, 136 and 155), which reduces the possibility of BAD heterodimerization by survival 
proteins of BCL-XL or BCL-2 cells. Phosphorylated BAA binds to 14-3-3 and is sequestered 
in the cytoplasm. Phosphorylation of ser-136 is associated with activation of Akt and phos-
phorylation of Ser-112 is due to the activation of the Ras-MAPK pathway. BAD Ser 155 is a 
large phosphorylation site that induces the formation of growth factors and is protected by 
inhibitors of protein kinase A.
It is known that FOXO3A gene prevails among long livers and probably determines longer 
life span, being one of the members of the family of transcription factors that mediate insulin 
action and resistance to stress. The relationship between polymorphisms of the FOXO3A gene 
and human life expectancy is presented in eight independent cohorts of centenarians [43]. 
Cell resistance to stress and cell survival in aging and DM may increase with high expression 
of the protein of the FOXO3A gene due to its effect on the activation of several members of the 
family of serum glucocorticoid-regulated kinases.
Genome-wide association studies (GWAS) have identified genes associated with DM and 
aging [44]. Most of the detected longevity genes have distant effect on one of the three 
Figure 1. Scheme of participation of IGF-1-signaling in the regulation of life expectancy (database of pathways of 
BioCarta).
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molecular pathways in the cell: insulin/IGF-1, sirtuins and mTOR. In the 1980s, scientists 
discovered the first gene that limited the lifespan of Caenorhabditis elegans and called it Age-
1. The effects of the gene Age-1 are realized through the molecular pathway of insulin/IGF-
1: when the activity of the gene Age-1 decreases, the molecular pathway of insulin/IGF-1 
decreases and the life of C. elegans lengthens. Recent studies have shown that in people with 
mutations in the pathway of insulin/IGF-1, the risk of developing DM may be reduced.
The sirtuin pathological pathway in the cell regulates the metabolism of the cell. In the 1990s, 
scientists from the Massachusetts Institute of Technology discovered an extrocopy of the 
equivalent of sirtuin, sirtuin 2, which increases the life span of yeast. mTOR pathway (mam-
malian target of rapamycin) plays a role in the aging processes of various organisms, con-
trolling the rate of protein synthesis, which is important for the functioning of the cell. The 
inhibition of this pathway in rapamycin mice leads to an increase in life expectancy [45].
The development of DM is associated with hyperlipidemia III and IV types. An example of 
a gene associated with healthy aging and long life expectancy is the cholesteryl ester trans-
fer protein gene. The homozygous variant 405VV of the CETP gene is associated with low 
concentrations of the CETP protein in the blood, high concentrations of HDL cholesterol and 
large HDL particles, which determines the protection of the human body from the develop-
ment of DM, cardiovascular diseases and Alzheimer’s disease [46].
The work of biological clock is determined by oscillatory genes and genes responsible for 
unidirectional movement of time (telomere activity). Oscillatory genes synchronize behav-
ioral and biochemical processes with a day/night cycle. Telomeres, which are repetitive series 
of DNA sequences that form terminal regions of chromosomes, are shortened during each 
subsequent division of the cell. The shortened telomeres are registered in various pathologi-
cal conditions associated with aging. The activity of all processes in human cells is supported 
by NADH and ATP, synthesized from nutrients. Limiting the intake of calories increases the 
level of AMP and NAD and healthy life span of animals. Silent Information Controller T1 
(SIRT1), NAD-dependent deacetylase, reduces the telomere reduction process, whereas the 
1α receptor activator γ, activated by the peroxisome proliferator-activated receptor γ coacti-
vator 1α (PGC-1α), is phosphorylated by kinase AMP and deacetylated SIRT1. Thus, PGC-1α 
is a key component of circadian oscillator that combines human biological clock and energy 
metabolism. Reactive forms of oxygen, formed in conditions of genetic mutation of biologi-
cal clocks, lead to an accelerated reduction of telomeres. The above-mentioned processes are 
described in patients with DM.
The Timeless gene (Tim) was found in Drosophila and encodes a protein that regulates the 
circadian rhythm [47]. Oscillations of mRNA and protein rhythmically occur in time as part 
of the work of negative coupling in the transcription-translation system involved in the work 
of the period (per) gene of the periodic oscillatory protein [48–50].
The timeless protein connects the cell cycle with the circadian rhythm in humans. In the model 
of “direct coupling,” two cycles are separated by key protein, the expression of which is deter-
mined by the circadian pattern [51]. The special role of the Tim gene in creating circadian 
rhythm is realized with the help of the Cry gene in humans. The transcription of the Cry and Per 
genes is activated by the CLOCK/BMAL1 complex and suppressed by the PER/CRY complex. 
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Timeless protein in humans (hTIM) is responsible for the production of electrical oscillations 
emanating from the suprachiasmatic nucleus of the hypothalamus (SCN) and determining for 
all circadian rhythms in the human body. This protein interacts with the key products of the 
activity of the oscillation genes CLOCK, BMAL, PER1, PER2 and PER3. Sancar et al. investi-
gated the role of hTIM in the work of cell cycle in humans [52]. It plays integral role in phases 
of G2/M and the intra-S cell cycle. In the G2/M phase of the cell cycle, hTIM binds the ATRIP 
subunit to the ATR protein kinase responsible for DNA damage. Binding of hTIM and ATR 
subsequently leads to phosphorylation of Chk1, resulting in cell cycle arrest or apoptosis. The 
Timeless gene influences to the development of human diseases. DNA damage associated with 
telomeres is increased in cells with reduced replication of the Timeless gene, along with disrup-
tion of telomere replication. Swi1 is a protein associated with the Timeless protein, which is 
responsible for DNA replication in the telomere region [53]. Single nucleotide polymorphism 
in the Timeless gene, which leads to the replacement of glutamine by arginine in the amino 
acid sequence of the protein, has not demonstrated an association with changes in morning or 
evening diurnal rhythms in humans [54]. The Timeless protein can be responsible for circadian 
rhythms in pancreatic β-cells [55]. It is believed that the Timeless protein can be identified as a 
kinase suppressor with Ras-1-like activity [56].
The telomeric zinc finger-associated protein (TZAP) associated with long telomeres that 
have low concentration of protective complex competing with TRF1 and TRF2 factors link-
ing telomeric repeats. In telomeres, TZAP causes a purification process that leads to rapid 
removal of telomere repeats. The regulation of the length of telomeres in human cells has 
been proposed: reduced concentration of protective complex in long telomeres leads to 
binding of TZAP protein and initiation of telomeres purification and sets an upper limit of 
telomere length [57]. Telomere shortening was previously associated with the development 
of DM in several pilot studies and in two large studies. Zee et al. showed that telomere 
length was less in the study group of patients with type 2 DM than in the control group 
(adjusted odds ratio = 1.748) [58].
Salpea et al. performed a study in which it was found that telomere length was less in type 
2 DM and this fact corresponded to a high level of oxidative stress in these patients. Short 
telomeres are an independent predictor of the progression of diabetic nephropathy (DN) in 
patients with type 1 DM in the early onset of the disease [59, 60]. Astrup et al. showed that 
short telomere length is the predictor of all causes of death in type 1 DM [61]. Short telo-
meres were detected in arterial wall cells in patients with type 1 and type 2 DM [62]. Patients 
with IGT demonstrated shorter telomere length compared to healthy controls, and patients 
with DM and severe atherosclerosis showed the presence of shorter telomeres compared with 
patients with DM without atherosclerosis. The presence of obesity and insulin resistance was 
associated with the length of telomere leukocytes in the adult population [63]. The study 
found direct causal relationship between telomerase activity and insulin secretion, as well as 
glucose tolerance: the TERC-/- mutation showed ITG, which was caused by impaired glucose-
stimulated insulin secretion from pancreatic islet cells due to a decrease in pancreatic cell size 
and replication damage of producing insulin β-cells [64].
Klass showed that the life expectancy of C. elegans could vary with the presence of the 
mutation of the Age-1 gene, and this effect is associated with caloric restriction [65]. Later, 
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Johnson showed that life expectancy increased to 65% due to the mutation of the Age-1 gene 
to greater extent than caloric restriction [66]. The Age-1 gene encodes catalytic subunit of 
class I phosphatidylinositol 3-kinase (PI3K). Ten years after Johnson’s research, the analysis 
of the daf-2 gene was performed, and Cynthia Kenyon demonstrated an increase in the half-
life of C. elegans [67].
Despite the fact that long livers can be characterized by unique set of genes, future biomedical 
research based on methods of high-performance screening of a pool of target molecules will 
lead to great advances in the diagnosis of aging stages and DM, as well as the development of 
methods for the prevention and therapy of accelerated aging of the human body and various 
violations of carbohydrate metabolism.
4. New technological platform for diagnostic and predictive 
pharmacology of aging stages and diabetes mellitus
Research in the field of aging and diabetology is related to recent discoveries in genomics and 
proteomics, new analytical equipment allows identifying biomarkers of aging and DM, the 
development of new drugs occurs through high-throughput screening of target molecules in 
human body [68].
At present, we have created unified technology platform for diagnostics and predictive 
pharmacology of aging and DM, taking into account interdisciplinary approach, including 
complex solution of problems of genomics, proteomics and metabolomics in the range of 
universal molecular pathways [69].
The technological platform for diagnostics and predictive pharmacology of DM includes 
three components taking into account a unique instrument base:
• Scientific component: Search for target biomarkers (α-β-subunit of insulin receptor, tyro-
sine kinase, MEK1/2-MAPK-cascade, Shc-Grb2-SOS-Ras–Raf mitogen, atypical isoforms of 
protein kinases, molecular cascade of GH/IGF-1, etc.) with aging and DM as the basis for 
a new level of diagnosis; the development of cellular technologies in the treatment of DM 
in combination with the development of new drugs based on targeted biomarkers; in vitro 
and in vivo studies of individual PK processes of drugs for the prevention of aging and 
treatment of DM; combining information on phenotypic manifestations of drug effects on 
the basis of pharmacoproteomic profile with the results of PK studies; PK/PD modeling; 
personalization of therapy for stages of aging and each type of DM.
• Technological component: New methods of genomic, proteomic, pharmacokinetic, pharma-
coprotein, pharmacogenomic studies; biomodeling; software on bioinformatics and for the 
registration of ADR; methods of visualization of molecular PD effects of drugs in biological 
fluids and body tissues; creation of bank of biosamples.
• Medical component: The introduction of technological platform for molecular diagnostics 
and drug monitoring in aging and DM, diagnostic of ADR, new biomolecular methods 
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of control and prevention of aging and complications of DM in the clinic; clinical trials of 
drugs; economic evaluation of the platform.
Methods of genomic and proteomic analysis of human biosamples at various stages of aging 
and aging-related DM are used most widely in biomedical research (Figure 2).
Modern systems for high-throughput screening (HTS) of molecules in cellular struc-
tures (for Image-Based High Content Screening, High Content Analysis and High 
Content Imaging) allow to investigate the proliferation and cytotoxicity, cell viability, 
cell cycles, the expression of nuclear, cytoplasmic proteins and plasma membrane pro-
teins, mitochondrial mass, phospholipidosis, signaling pathways, the increase and the 
decrease of nuclear sizes, apoptosis and fragmentation of nuclei. These systems allow 
performing complex analysis of cellular structures in real time, obtaining universal 
biological information about the development of aging processes and related diseases 
at the molecular level in the cell. Model of diabetic cardiomyopathy has been developed 
with the help of Operetta High Content Screening (Perkin Elmer, UK)—the system of 
high-performance screening of cell structures. The ways of pharmacological influence 
on the key targets of the development of this complication of DM have been devel-
oped. The model of this state in vitro was developed taking into account reproduced 
environmental conditions and genetic factors from human pluripotent stem cells of 
cardiomyocytes.
Figure 2. Molecular pattern of patient's biosample, obtained  by methods of proteomic analysis (two-dimensional 
polyacrylamide gel electrophoresis, MALDI-TOF-MS, HPLC / MS / MS).
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Biochemistry of DM was obtained, which stimulates the development of the phenotype of 
cardiomyopathy and which allowed us to analyze structural and functional changes in car-
diomyocytes. The cardiomyopathic phenotype was reproduced definitively in specific cells of 
patients and determined by the initial clinical status. In vitro model was included in the stages 
of screening platform that identifies drugs that prevent the development of the phenotype of 
cardiomyopathy [70].
Thus, the current stage in the development of biomedical research in the field of aging and 
DM is associated with the introduction of new technology platform for HTS of molecules in 
human cells and the pharmacology of the aging stages and all types of DM.
The newest biomedical tools of the twenty-first century are biological microchips (biochips, 
DNA microarrays). Developed biological microchips make it possible to realize in an acces-
sible form very complex integrative approaches of genomics, proteomics and selomics. An 
important medical application of biochips is the early diagnosis of DM and the development 
of new therapy, as well as the correlation of diagnostic markers of DM with diagnostic mark-
ers of stages of aging of the human body. Researchers conduct on-chip simultaneous analy-
sis of tens of thousands of genes and compare the expression of these genes in healthy and 
diseased cells. Biochips are also an indispensable tool for biomedical research, which can in 
one experiment recognize the influence of various factors (drugs, proteins, nutrition) on the 
work of tens of thousands of genes. The effectiveness of biochips is due to the possibility of 
parallel carrying out a huge number of specific reactions and interactions of molecules of 
biopolymers, such as DNA, proteins and polysaccharides, with each other and low molecular 
ligands. The task is to quickly and effectively determine the concentration of the desired com-
pound, for example, glucose for people with DM.
The use of protein chips for search of markers of aging and DM is promising direction. The 
following two tasks are of particular interest: simultaneous qualitative and quantitative deter-
mination of large number of proteins in cells of various tissues or in various functional states; 
study of interactions of cellular proteins with each other and other cellular ligands (DNA, low 
molecular compounds).
Bioelectronic devices are able to raise the quality of medical analyzes to new level, they will 
contribute to a one-stage definition of stages of aging and early diagnosis of DM.
Highly sensitive oligonucleotide microarrays were used to evaluate mRNA levels and iden-
tify transcriptional profiles of fibroblast cultures obtained from donors of different ages. The 
mRNA levels were measured in actively dividing fibroblasts isolated from young, middle-aged 
and elderly patients, as well as patients with progeria. The study identified genes, the expres-
sion of which is associated with phenotypes of different age groups and diseases. The aging 
process is based on a mechanism that includes an increasing number of errors in the mitosis of 
dividing cells at the post-productive stage of human life [71].
The progress and development of biosensors used in the clinic was related to the devel-
opment of glucose biosensor in the 1960s and obtained on the basis of early integration of 
the redox enzyme glucose oxidase with an oxygen electrode [72]. New materials, sensory 
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configurations and technical innovations have been proposed for the determination of glu-
cose [73–75]. Currently, glycemic control is based on the study of blood glucose, which still 
requires frequent blood sampling with a certain degree of inconvenience. Despite the inten-
sive application of the existing method of blood glucose testing, precise monitoring of glucose 
fluctuations during the day cannot yet be performed. Therefore, today, subcutaneous bio-
sensors are used, which measure glucose periodically during the day [76, 77]. However, the 
creation of an accurate implantable biosensor for glucose, acceptable for patients with DM, 
is an open question. Today, the most promising results were obtained on biosensors, which 
are based on amperometric detection of hydrogen peroxide formed by enzymes immobilized 
on electrodes. Updike et al. created a biosensor for glucose, implanted subcutaneously, with 
maximum duration of up to 5 months [78].
Interstitial levels of lactate should reflect its systemic level when hypoxia appears in the tis-
sues. There is an opportunity to control lactate in vivo in the interstitium; however, it is dif-
ficult to introduce monitoring methods into the clinic because of their unreliability due to 
the influence on the level of lactate of a lot of endogenous factors. Several types of biosen-
sors for the determination of lactate are presented in the literature. A microfluidic biochip 
was developed, which is integrated with a highly sensitive fiber-optic biosensor of glucose. 
Experimental results showed that the biochip determines an ultra-low glucose concentration 
(1 nM) [79]. Due to the fact that DM as an aging-related disease progresses and due to com-
plex and stepwise processes of malfunctioning of the pancreatic β-cells at the molecular level 
that can be registered in the blood, early detection of DM requires the use of supersensitive 
systems for detecting molecular changes. To this end, a protein microchip was developed, 
including the use of polyfluorophor technology. The innovative system is characterized by 
high sensitivity: the possibility of the determining of biomarkers at the level of femtograms in 
10 μl of the biosample is 92% within 10 minutes [80].
It is believed that the stages of aging and related diseases, including DM, are characterized by 
their bar code—a change in the level of transcription of a set of genes specific for this disease. 
It is assumed that in the future, according to the barcode, changes in the expression in particu-
lar set of genes can be diagnosed with specific diseases and the stages of their development 
and, consequently, develop targeted treatment regimen.
At present, bioinformatics is ready to provide data about tens of thousands of new drug tar-
gets, predicting the function of genes and deciphering the sequence of proteins. Promising 
bioinformatic developments are presented in such sections of medicine as gerontology and 
diabetology. The main directions of bioinformatics are distinguished, depending on the 
objects of study: sequence bioinformatics, structural bioinformatics and computer genomics. 
The main task of bioinformatics in the development of new drugs is to provide technologies 
that allow the formation of target targets for directed action of drug having specific structure 
for this target.
Today, an extended analysis is available, including the molecular pathways presented 
in most databases; so, large array of information about altered proteins can be obtained, 
including their expression and/or post-translational modifications in molecular pathways. 
Comparative analysis of two web products for the analysis of pathways and intermolecular 
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interactions—Ingenuity Pathway Analysis (IPA) and STRING—is published. Data about key 
proteins, participating in molecular pathological pathways (Wnt, APP, insulin signaling, 
mitochondrial apoptosis, tau-phosphorylation), were obtained on the basis of medical lit-
erature and data of proteomic analysis of the HEK293 cell line.
Information about protein interactions in complexes is found in databases such as MINT, 
BioGRID, IntAct or HRPD. It is possible to provide high percentage of predicted pro-
tein-protein interactions and interactions based on literature data (PubMed database). 
Widely used web resource for the analysis of inter-protein interactions STRING is not 
only a database but also linked to several other resources with large volume of literature 
sources [81]. The Cytoscape graphical tool allows us to create network interactions of 
high degree of complexity. Recently, web platform has been launched that integrates data 
on molecular pathways for the development of pathological processes and the analysis 
of intermolecular interactions, including six different databases (KeGG, Bio-Carta, Gene 
Ontology, Reactome, Wiki, NCI pathways) and interacts functionally with database on 
molecular activity of proteins (Interpro) and database of complex information about pro-
teins (Corum).
Identification of the protein in the study of the biosample should be accompanied by a detailed 
analysis of its primary, secondary and tertiary structure, as well as its post-translational modi-
fications and intermolecular interactions (BLAST search engine). The amino acid sequence of 
the protein can be analyzed in software products such as Pfam, Interpro, SMART or DAVID 
[82], whereas sequence analysis of post-translational protein modifications can be performed 
using algorithms such as MotifX or PhosphoMotif [83].
Modern methods of proteomic and bioinformatic analysis allow us to investigate key 
genomic-proteomic interactions that underlie DN in patients with type 2 DM. The study of 
the formation and development of DN can become the model for studying molecular path-
ways of aging of kidney tissue [84].
We carried out prospective comparative cohort study with parallel design for the search of 
molecular prognostic markers of DN of different stages using methods of proteomics and 
bioinformatic analysis on the basis of the Department of Nephrology of the Dagestan State 
Medical University (Makhachkala, Dagestan, Russia) and the Department of Nephrology of 
the Rostov State Medical University (Rostov-on-Don, Russia), MC “Novomeditsina” (Rostov-
on-Don, Russia) [85]. It included 205 patients with T2DM and DN (stages 1–4). Patients cor-
responded to the criteria for the DN classification proposed by the Committee on Diabetic 
Nephropathy [86]. The duration of DN was 10.5 years. Molecular phenotyping of biosamples 
(urine) was processed with methods of proteomics: the prefractionation, the separation of 
proteins with standard sets (MB-HIC C8 Kit, MB-IMAC Cu, MB-Wax Kit, «Bruker», USA) 
and matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-
TOF-MS/MS, Ultraflex II, «Bruker», USA). The partially identified sequences were then sub-
mitted to “BLAST protein-protein” and screened against the Homo sapiens Swissprot database 
to check if this identification matched the MASCOT-identification (Matrix Science). The data 
of the molecular interactions and functional features of proteins were received with STRING 
10.0 database.
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Protein name Group 1 (n = 42) Group 2 (n = 48) Group 3 (n = 65) Group 4 (n = 50) Control group 
(n = 30)
MW (Dа) Functional process (sources: InterPro, 
Entrez, SWISS-PROT, NRDB, PDB, 
KEGG
TGF-β1 18 PCG-1 = 0.001 27 PCG-2 = 0.000 52 PCG-3 = 0.000 48 PCG-4 = 0.000 2 44,341 Pro-fibrotic and anti-inflammatory 
activities, the regulation of tubular 
EMT
E-cadherin 22 PCG-1 = 0.000 38 PCG-2 = 0.000 62 PCG-3 = 0.000 49 PCG-4 = 0.000 1 97,456 The regulation of tubular EMT; the 
maintenance of epithelial integrity, 
cell phenotype; the progression of 
renal fibrosis
Cystatin C 15 PCG-1 = 0.001 40 PCG-2 = 0.000 60 PCG-3 = 0.000 45 PCG-4 = 0.000 1 15,799 Cysteine proteinase inhibitor, tubular 
damage marker
Collagen IV 4 PCG-1 > 0.05 32 PCG-2 = 0.000 48 PCG-3 = 0.000 42 PCG-4 = 0.000 1 164,038 Constituent of mesangial matrix, 
marker of the phase of compromised 
renal filtration function
MMP 9 8 PCG-1 > 0.05 32 PCG-2 = 0.000 60 PCG-3 = 0.000 49 PCG-4 = 0.000 1 78,458 Potent modulator of ECM turnover 
and also of shedding of syndecans
Fibronectin 4 PCG-1 > 0.05 35 PCG-2 = 0.000 52 PCG-3 = 0.000 43 PCG-4 = 0.000 1 262,625 Adhesive glycoprotein, locally 
stimulated mesangial and epithelial 
cell production
NGAL 10 PCG-1 = 0.043 42 PCG-2 = 0.000 62 PCG-3 = 0.000 48 PCG-4 = 0.000 1 22,588 Kidney development; it loses through 
the damaged glomerulus, injured 
tubular cells produce NGAL as a 
compensatory mechanism against 
intracellular oxidative stress and 
complement- induced apoptosis.
Ceruloplasmin 12 PCG-1 = 0.006 37 PCG-2 = 0.000 42 PCG-3 = 0.000 35 PCG-4 = 0.000 1 122,205 Marker of damaged glomerulus
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Protein name Group 1 (n = 42) Group 2 (n = 48) Group 3 (n = 65) Group 4 (n = 50) Control group 
(n = 30)
MW (Dа) Functional process (sources: InterPro, 
Entrez, SWISS-PROT, NRDB, PDB, 
KEGG
β2-microglobulin 6 PCG-1 > 0.05 37 PCG-2 = 0.000 62 PCG-3 = 0.000 49 PCG-4 = 0.000 1 11,774 The indicator of incipient DN; 
detecting injured epithelial cells in the 
proximal tubules
Podocin 23 PCG-1 = 0.000 45 PCG-2 = 0.000 63 PCG-3 = 0.000 49 PCG-4 = 0.000 1 42,201 Podocyte-specific protein, interact 
with the PI3K/AKT-signaling pathway 
for maintenance of functional integrity
MCP-1 11 PCG-1 = 0.011 39 PCG-2 = 0.000 48 PCG-3 = 0.000 46 PCG-4 = 0.000 1 2583 Chemotactic factor for monocytes; 
regulates the memory T lymphocytes, 
NK cells; increases with TNFα and 
IL-6 in damaged kidneys
Table 1. Qualitative profile of urine proteins in T2DM patients with DN.
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All changes in patients with DN are associated with a higher expression of urine proteins in 
the progression of epithelial-to-mesenchymal transition (EMT) and changes in the extracel-
lular matrix (ECM) in kidneys in T2DM patients with DN (Table 1). Proteomic analysis helps 
in the detection of differences in the component composition of the urine proteins in patients 
with DN of varying stages compared with the control group. Molecules interact among them-
selves and with other molecules as participants in universal pathways in T2DM patients with 
DN, which are the key elements for EMT formation and changes in ECM: Smad, p38 MAPK, 
TLRs, Wnt, mTOR, Notch, small GTPase and Hedgehog and PI3K/AKT-signaling pathways.
Each protein molecule in the functional group interacts with other protein molecules. For 
example, the molecular interactions of NGAL are presented in Figure 3. The concentra-
tion of NGAL increases in the urine of T2DM patients with DN. The study identified the 
biomarkers of tubular damage that have a key role in the development and progression of 
DN. The research into signaling pathways and molecules that are involved in ECM forma-
tion may help in developing strategies to prevent DN. Molecular pathways for the develop-
ment of DN constitute a model for the study of molecular pathways in the development of 
aging of kidney tissue.
Figure 3. Molecular interactions of NGAL (STRING 10.0 database). LCN2, lipocalin-2; MMP-9, matrix metallopeptidase 
9; LRP2, low density lipoprotein-related protein 2; ERBB2, erythroblastic leukemia viral oncogene homolog 2 (neuro/
glioblastoma derived oncogene homolog); IL3, interleukin 3 (colony-stimulating factor, multiple); HMOX1, heme 
oxygenase (decycling) 1; IL-17A, interleukin 17A; LEP, leptin; INS, insulin; TLR2, toll-like receptor 2 and CDH1, cadherin 
1, type 1, E-cadherin (epithelial cadherin).
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Thus, the future progress in biomedical research of the aging stages of the human body and 
DM is associated with the development of experimental genomics, transcriptomics, pro-
teomics and selomics and with the development of typical human development scenario, 
starting from the postnatal period on the basis of modern technological platforms. The devel-
opment of methods for the systematic analysis of molecular interactions in cell and the sub-
sequent study of their functional activity makes it possible to discover new pathways for the 
development of human pathology associated with aging.
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